SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study)

Authors: Borghaei, Hossein, Redman, Mary W., Kelly, Karen, Waqar, Saima N., Robert, Francisco, Kiefer, Gauri J., Stella, Philip J., Minichiello, Katherine, Gandara, David R., Herbst, Roy S., Papadimitrakopoulou, Vassiliki A.

Source: In Clinical Lung Cancer May 2021 22(3):178-186

Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704

Authors: Bitterman, Danielle S., Winter, Kathryn A., Hong, Theodore S., Fuchs, Charles S., Regine, William F., Abrams, Ross A., Safran, Howard, Hoffman, John P., Benson, Al B., Kasunic, Timothy, Mulcahy, Mary, Strauss, James F., DiPetrillo, Thomas, Stella, Philip J., Chen, Yuhchyau, Plastaras, John P., Crane, Christopher H.

Source: International journal of radiation oncology, biology, physics. 109(1):201-211

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100133093907.0x000001&indx=1&recIds=ETOCvdc_100133093907.0x000001

This result is not displayed to guests.
Login for full access.

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

Authors: Smith, John W., II, Buyse, Marc E., Rastogi, Priya, Geyer, Charles E., Jr., Jacobs, Samuel A., Patocskai, Erica J., Robidoux, André, Conlin, Alison K., Ansari, Bilal, Keogh, George P., Stella, Philip J., Gross, Howard M., Lord, Raymond S., Polikoff, Jonathan A., Mauquoi, Celine, Mamounas, Eleftherios P., Swain, Sandra M., Wolmark, Norman

Source: In Clinical Breast Cancer February 2017 17(1):48-54

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Authors: Neal, Joel W, Dahlberg, Suzanne E, Wakelee, Heather A, Aisner, Seena C, Bowden, Michaela, Huang, Ying, Carbone, David P, Gerstner, Gregory J, Lerner, Rachel E, Rubin, Jerome L, Owonikoko, Taofeek K, Stella, Philip J, Steen, Preston D, Khalid, Ahmed Ali, Ramalingam, Suresh S

Source: In The Lancet Oncology December 2016 17(12):1661-1671

A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621

Authors: Molina, Julian R., Foster, Nathan R., Reungwetwattana, Thanyanan, Nelson, Garth D., Grainger, Andrew V., Steen, Preston D., Stella, Philip J., Marks, Randolph, Wright, John, Adjei, Alex A.

Source: In Lung Cancer August 2014 85(2):245-250

Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501)

Authors: Aisner, Joseph, Manola, Judith B., Dakhil, Shaker R., Stella, Philip J., Sovak, Mika A., Schiller, Joan H.

Source: In Journal of Thoracic Oncology August 2013 8(8):1075-1083

A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

Authors: Dy, Grace K., Mandrekar, Sumithra J., Nelson, Garth D., Meyers, Jeffrey P., Adjei, Araba A., Ross, Helen J., Ansari, Rafat H., Lyss, Alan P., Stella, Philip J., Schild, Steven E., Molina, Julian R., Adjei, Alex A.

Source: In Journal of Thoracic Oncology January 2013 8(1):79-88

Provider Perspective on the Payer Perspective: What's in It for Me?
Quality care symposium

Authors: Stella, Philip J., Harrison, Kimberley A.

Source: Journal of oncology practice. 11(3):182-184

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCCN600198383&indx=1&recIds=ETOCCN600198383

Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial

Authors: Tan, Winston W., Allred, Jacob B., Salim, Muhammad, Flynn, Patrick, Fishkin, Paul A.S., Stella, Philip J., Wiesenfeld, Martin, Bernath, Albert M., Fitch, Tom R., Perez, Edith A.

Source: In Clinical Breast Cancer April 2012 12(2):81-86

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer

Authors: Heath, Elisabeth, Heilbrun, Lance, Mannuel, Heather, Liu, Glenn, Lara, Primo, Monk, J. Paul, Flaig, Thomas, Zurita, Amado, Mack, Philip, Vaishampayan, Ulka, Stella, Philip, Smith, Daryn, Bolton, Susan, Hussain, Arif, Al‐Janadi, Anas, Silbiger, Daniel, Usman, Muhammad, Ivy, S. Percy

Source: Oncologist. 24(9):1149-e807

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100088011777.0x000001&indx=1&recIds=ETOCvdc_100088011777.0x000001

Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting

Authors: Croghan, Gary A., Sloan, Jeff A., Croghan, Ivana T., Novotny, Paul, Hurt, Richard D., DeKrey, Wanda L., Mailliard, James A., Ebbert, Larry P., Swan, Debra K., Walsh, Daniel J., Wiesenfeld, Martin, Levitt, Ralph, Stella, Philip, Johnson, Patricia A., Tschetter, Loren K., Loprinzi, Charles

Source: Nicotine & Tobacco Research, 2003 Apr 01. 5(2), 181-187.

Access URL: https://www.jstor.org/stable/26759322

E4206: AMG 706 and Octreotide in Patients with Low‐Grade Neuroendocrine Tumors

Authors: Lubner, Sam, Feng, Yang, Mulcahy, Mary, O'Dwyer, Peter, Giang, Guang‐Yu, Hinshaw, J. Louis, Deming, Dustin, Klein, Leonard, Teitelbaum, Ursina, Payne, Jennifer, Engstrom, Paul, Stella, Philip, Meropol, Neal, Benson, Al

Source: Oncologist. 23(9):1006-e104

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100082764872.0x000001&indx=1&recIds=ETOCvdc_100082764872.0x000001

Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

Authors: Jatoi, Aminah, Dakhil, Shaker R., Foster, Nathan R., Ma, Cynthia, Rowland, Kendrith M., Jr, Moore, Dennis F., Jr, Jaslowski, Anthony J., Thomas, Sachdev P., Hauge, Mark D., Flynn, Patrick J., Stella, Philip J., Alberts, Steven R.

Source: In Journal of Thoracic Oncology May 2008 3(5):516-520

The prevalence of weight concerns in a smoking abstinence clinical trial

Authors: Clark, Matthew M., Hurt, Richard D., Croghan, Ivana T., Patten, Christi A., Novotny, Paul, Sloan, Jeff A., Dakhil, Shaker R., Croghan, Gary A., Wos, Edward J., Rowland, Kendrith M., Bernath, Albert, Morton, Roscoe F., Thomas, Sachdex P., Tschetter, Loren K., Garneau, Stewart, Stella, Philip J., Ebbert, Larry P., Wender, Donald B., Loprinzi, Charles L.

Source: In Addictive Behaviors 2006 31(7):1144-1152

SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)

Authors: Langer, Corey J., Redman, Mary W., Wade, James L., III, Aggarwal, Charu, Bradley, Jeffrey D., Crawford, Jeffrey, Stella, Philip J., Knapp, Mark H., Miao, Jieling, Minichiello, Katherine, Herbst, Roy S., Kelly, Karen, Gandara, David R., Papadimitrakopoulou, Vassiliki A.

Source: In Journal of Thoracic Oncology October 2019 14(10):1839-1846

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.

Authors: Lipsyc-Sharf, Marla, Ou, Fang-Shu, Yurgelun, Matthew B, Rubinson, Douglas A, Schrag, Deborah, Dakhil, Shaker R, Stella, Philip J, Weckstein, Douglas J, Wender, Donald B, Faggen, Meredith, Zemla, Tyler J, Heying, Erica N, Schuetz, Samantha R, Noble, Stephanie, Meyerhardt, Jeffrey A, Bekaii-Saab, Tanios, Fuchs, Charles S, Ng, Kimmie

Source: Oncologist; Apr2022, Vol. 27 Issue 4, p292-298, 7p, 1 Diagram, 2 Charts, 1 Graph

Subject Terms: RESEARCH, DISEASE progression, CONFIDENCE intervals, EPIDERMAL growth factor receptors, MONOCLONAL antibodies, IRINOTECAN, ANTINEOPLASTIC agents, METASTASIS, COLORECTAL cancer, RANDOMIZED controlled trials, TREATMENT effectiveness, CANCER patients, BLIND experiment, BEVACIZUMAB, STATISTICAL sampling, PROGRESSION-free survival, DRUG side effects, DRUG toxicity, PHARMACODYNAMICS

Docetaxel for Malignant Mesothelioma: Phase II Study of the Eastern Cooperative Oncology Group

Authors: Belani, Chandra P., Adak, Sudeshna, Aisner, Seena, Stella, Philip J., Levitan, Nathan, Johnson, David H.

Source: In Clinical Lung Cancer July 2004 6(1):43-47

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.

Authors: Ganz, Patricia A., Bandos, Hanna, Geyer Jr., Charles E., Robidoux, André, Paterson, Alexander H. G., Polikoff, Jonathan, Baez-Diaz, Luis, Brufsky, Adam M., Fehrenbacher, Louis, Parsons, Ann W., Ward, Patrick J., Provencher, Louise, Hamm, John T., Stella, Philip J., Carolla, Robert L., Margolese, Richard G., Shibata, Henry R., Perez, Edith A., Wolmark, Norman

Source: Breast Cancer Research & Treatment; Feb2022, Vol. 192 Issue 1, p153-161, 9p

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Authors: Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A.

Source: Nature Medicine; May 2022, Vol. 28 Issue: 5 p939-945, 7p